Aveo's tivozanib fails in Phase II colorectal cancer study
This article was originally published in Scrip
Executive Summary
Aveo Oncology announced yet another failure in a long line of setbacks for the cancer drug tivozanib on 13 December: an interim assessment has shown that the drug is not likely to meet the primary endpoint in the Phase II BATON clinical trial in the treatment of colorectal cancer (CRC).